Periperal blood-derived CD34+ stem cells for treatment of Crohn's disease

The objective of this study is to evaluate the safety and effectiveness of high-dose chemotherapy followed by infusion of autologous CD34+ peripheral blood stem cells (PBSCs)  in pediatric and young adult patients with severe Crohn's disease. T-cells in the CD34+ PBSC product are significantly depleted and thus could contribute to eradication of autoimmune T cell clones which are considered a main factor in the sustained state of inflammation in Crohn's disease.